Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Source: Newsfilter
Strategic Review Announcement: Liminatus Pharma, Inc. has initiated a strategic review to explore the creation of a dedicated digital asset investment vehicle aimed at diversifying its long-term treasury strategy, potentially targeting up to $500 million in capital formation.
Compliance and Future Plans: The proposed initiative is still under consideration and requires final Board approval, regulatory compliance, and market conditions; no capital has been raised or partnerships established yet.
Analyst Views on LIMN
About LIMN
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies. The Company is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
